Cover Image
市場調查報告書

皮膚科處方藥的全球市場 第9版:抗粉刺,抗老化,皮膚炎,掉頭髮,乾癬,皮膚癌,肝斑,及脂漏性皮膚炎的治療

World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)

出版商 Kalorama Information 商品編碼 233324
出版日期 內容資訊 英文 446 Pages
訂單完成後即時交付
價格
Back to Top
皮膚科處方藥的全球市場 第9版:抗粉刺,抗老化,皮膚炎,掉頭髮,乾癬,皮膚癌,肝斑,及脂漏性皮膚炎的治療 World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
出版日期: 2015年08月19日 內容資訊: 英文 446 Pages
簡介

全球皮膚科處方藥市場上的主要促進要素有全球人口高齡化、新產品與技術,以及高齡、改善對皮膚的負面影響之生活型態治療等。醫藥品產業內就整體來看,金融不景氣、整合及經濟低迷對市場的影響。

本報告涵括全球皮膚科處方藥市場,提供您抗粉刺,抗老化,治療皮膚炎,掉頭髮,乾癬,皮膚癌,肝斑,及脂漏性皮膚炎等各種皮膚疾病的處方藥之詳細分析,同時彙整各種市場規模與研究開發趨勢,未來的預測,加上主要的市場參與企業簡介等資訊。

第1章 摘要整理

第2章 簡介

  • 皮膚的結構與機能
    • 表皮
    • 真皮
    • 皮下組織
    • 表皮附屬物
  • 皮膚功能
  • 老齡化對皮膚的影響
  • 皮膚的症狀和治療
  • 藥物動力學
    • 藥物吸收
    • 分配
    • 生物有效性 (生物利用性)
  • 藥物遞輸手法
  • 皮膚疾病的人口統計資料,發病率,及罹患率

第3章 課題與趨勢

  • 患者的適合性
  • 美容皮膚科醫生
  • 防曬油的利用
  • 黑色素瘤存活率的低迷
  • 室內曬黑的問題
  • 磷脂和牛皮癬
  • 新的填充材選擇
  • 消費者的混亂
  • 乾癬的遺傳相關性
  • 生物學的皮膚科學
  • 處方藥改列成藥 (Rx-to-OTC Switch)
  • 藥用化妝品
    • 抗氧化劑
    • 多胜肽
  • 皮膚學
  • 給付問題
  • 市場微創治療朝向
  • Medi-Spas
    • 社會對外表的注重
  • 法規的影響:美國·全球
  • 健康保險計劃·治療費的影響
  • 競爭的影響因素:市場·治療模式的影響
  • 雷射治療
  • 窄頻UVB
  • 光線動態的療法
  • PYCR1 遺傳基因
  • 信用卡條件的變化
  • 患者保護排列醫療費負擔合理化法 (PPACA)
  • Thermage
  • BRAF遺傳基因
  • 新的口服藥和粉刺的研究
  • 皮膚治療用合成脂質
  • 藥物遞輸的重要性
  • 產業的投稿

第4章 坑粉刺及酒糟處方藥

  • 疾病概要
  • 產品概要
    • 過氧化苯甲醯
      • 產品的說明
      • 目前供應商
    • 類視色素
      • 局部處方藥
        • All-trans-Retinoic Acid (tretinoin )
        • Adapalene
        • Tazarotene
      • 全身處方藥
        • Isotretinoin
      • 目前供應商
    • 抗生素
      • 產品的說明
        • 杜鵑花酸(壬二酸)
        • Clindamycin
        • Erythromycin
        • Metronidazole
        • 其他
      • 目前供應商
    • 口服避孕藥
  • 研究開發
  • 市場規模與成長
    • 全球市場
    • 各地區市場
      • 美國
      • 歐洲
      • 日本
      • 其他
  • 市場未來
  • 競爭分析

第5章 抗老化及光損傷處方藥

  • 概要
  • 產品概要
    • 角質溶解藥
    • 保濕藥
    • 類視色素
    • 防曬油
    • 肉毒桿菌·填充劑
  • 研究開發
  • 市場規模與成長
    • 全球市場
    • 各地區市場
      • 美國
      • 歐洲
      • 日本
      • 其他
  • 市場未來
  • 競爭分析

第6章 皮膚炎及脂漏性皮膚炎處方藥

  • 概要
  • 產品概要
    • 局部皮質類固醇藥
    • 全身皮質類固醇藥
    • 其他的產品
  • 研究開發
  • 市場規模與成長
    • 全球市場
    • 各地區市場
      • 美國
      • 歐洲
      • 日本
      • 其他
  • 市場未來
  • 競爭分析

第7章 抗真菌處方藥

  • 概要
  • 產品概要
    • 全身處方藥
    • 局部處方藥
  • 研究開發
  • 市場規模與成長
    • 全球市場:各類型
    • 各地區市場
  • 市場未來
  • 競爭分析

第8章 掉頭髮及脫毛處方藥

  • 概要
  • 產品概要
    • 抗雄激素
    • 雄激素抑制劑
    • 其他的治療藥物
  • 研究開發
  • 市場規模與成長
  • 全球市場
  • 各地區市場
  • 市場未來
  • 競爭分析

第9章 高色素沉著及肝斑處方藥

  • 概要
  • 產品概要
  • 市場規模與成長
  • 研究開發
  • 全球市場
  • 各地區市場
  • 市場未來
  • 競爭分析

第10章 乾癬處方藥

  • 概要
  • 產品概要
    • 主要的局部乾癬產品
    • 主要的全身乾癬製劑
    • 光線療法
    • 生技藥品
  • 研究開發
  • 市場規模與成長
  • 全球市場
  • 各地區市場
  • 市場未來
  • 競爭分析

第11章 皮膚癌處方藥

  • 概要
    • 非黑色素瘤皮膚癌
      • 紫外線角化症
      • 基底細胞癌
      • 扁平表皮細胞癌症
      • 皮膚T細胞淋巴瘤
      • Dysplastic Nevus Syndrome
    • 惡性黑色素瘤
  • 產品概要
  • 研究開發
  • 市場規模與成長
  • 全球市場
  • 各地區市場
  • 市場未來
  • 競爭分析

第12章 其他皮膚疾病治療藥

  • 概要
    • 坑病毒劑
    • 坑寄生蟲劑
  • 產品概要
    • 坑病毒劑
    • 坑寄生蟲劑
  • 其他皮膚相關產品
  • 研究開發
  • 市場規模與成長
    • 全球市場
  • 各地區市場
  • 市場未來
  • 競爭分析

第13章 全球市場的摘要

  • 概要
  • 市場規模及預測
  • 市場分析:各國
    • 美國
    • 歐洲
    • 日本
    • 其他
  • 市場與競爭分析

第14章 企業簡介

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: KLI5670561

The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin as well as the effects of aging. It's a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing.

The field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options available to physicians has expanded.This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the ninth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future.

The driving forces for this market include growth and aging of the worldwide population, new products and technologies, and focus on lifestyle treatments that improve the effects of aging and damage to the skin. Within the pharmaceutical industry as a whole, financial depression, consolidation and economic downturns have influenced the market.

The worldwide market for prescription dermatology drugs includes products in the following categories:

  • Prescription Acne and Rosacea Drugs
  • Prescription Antiaging and Photodamage Drugs
  • Prescription Dermatitis and Seborrhea Drugs
  • Prescription Fungal Infection Drugs
  • Prescription Hair Loss and Hair Removal Drugs
  • Prescription Hyperpigmentation/Melasma Drugs
  • Prescription Psoriasis Drugs
  • Prescription Skin Cancer Drugs
  • Other Prescription Skin Disorder Drugs

This report details the various categories of prescription dermatological drugs, describes the worldwide market for prescription dermatological drugs, and identifies major market factors that may help to shape the worldwide market for prescription dermatological drugs in the future.

The pharmaceutical industry is facing a tougher environment in general, due to harder regulations for gaining approvals for mainstream products, economic issues, and a dwindling pipeline of new products. Reliance on blockbuster drugs is all but over, causing a shift of focus for many drug research and development entities. By focusing on cosmetic medications, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology. This transition will play a role in the future development of the dermatological industry over the forecast period. The worldwide pharmaceutical sector has little choice but to continue expanding through mergers and acquisitions for some time to come. The sector is ripe for the picking, too, with the financial crisis having created an impressive buyer's market for larger companies, as smaller firms struggle to extend financing. True globalization of pharmaceuticals has arrived. Most of the growth in the next few years will be outside the US, Europe and Japan. It's a very dynamic time for the industry focusing on a worldwide market.

The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the dermatology market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 30 industry executives and product managers to validate and obtain expert opinion on current and future trends in the dermatological market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.

All market data pertains to the worldwide market at the manufacturers' level. Data are expressed in current U.S. dollars. The base year for data was 2015. Historical data are provided for each of the years 2013 to 2014, and forecast data are provided for each of the years 2015 through 2020. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2015 base year.

The following companies are profiled in this report:

  • Allergan Inc.
  • Allergan Inamed Corporation
  • Barrier Therapeutics, Inc
  • Bayer AG
  • PharmaDerm Pharmaceuticals, Inc
  • Bristol-Myers Squibb
  • Collagenex (now Galderma) Pharmaceuticals
  • Galderma S.A.
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil)
  • Medicis Pharmaceutical Corporation
  • Merck & Company, Inc.
  • Mylan Pharmaceuticals, Inc,
  • Novartis Pharmaceuticals Corporation
  • Nycomed Inc.
  • Pfizer, Inc.
  • Q-Med AB
  • Roche Group (F. Hoffmann-La Roche Ltd.)
  • Schering (now Merck)-Plough Corporation
  • Sinclair Pharma Plc.
  • SkinMedica
  • Stiefel Laboratories, Inc.
  • Valeant Pharmaceuticals, Inc.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Competitor Analysis

CHAPTER TWO: INTRODUCTION

  • Structure and Function of the Skin
  • Epidermis
  • Dermis
  • Subcutaneous Tissue
  • Epidermal Appendages
  • Functions of the Skin
  • Effects of Aging on the Skin
  • Dermatological Conditions and Treatment
  • Pharmacokinetics
  • Drug Absorption
  • Distribution
  • Bioavailability
  • Drug Delivery Methods
  • Demographics of Skin Disorders, Incidence, and Prevalence

CHAPTER THREE: ISSUES AND TRENDS

  • Patient Compliance
  • Cosmetic Dermatologists
  • Sunscreen Use
  • Melanoma Survival Rates Falter
  • Indoor Tanning Issue
  • Phosphatidylglycerol and Psoriasis
  • New Filler Options
  • Consumer Confusion
  • Genetic Link to Psoriasis
  • Biologic Dermatology
  • Rx-to-OTC Switches
  • Cosmeceuticals
  • Antioxidants
  • Polypeptides
  • Teledermatology
  • Reimbursement Issues
  • Market Shift Towards less invasive Procedures
  • Medi-Spas
  • Combination therapies Thrive
  • Competitive, Economic, Social Forces Driving Market Demand
  • Society's Obsession with Physical Appearance
  • Regulatory Influences: US & International
  • International Authorities
  • U.S. FDA & Other Regulatory Agencies
  • Effects of Health Insurance Programs & Treatment Costs
  • Competitive Influences-Impact on Market & Treatment Modalities
  • Facial Skin--Bio-Physiology
  • The “Gray Areas” of Medicine
  • Laser Therapy
  • Narrowband Ultraviolet B
  • Photodynamic Therapy
  • PYCR1 Gene
  • Changes in Credit Card Terms
  • Patient Protection and Affordable Care Act
  • Thermage
  • BRAF Gene
  • New Oral Medications and Research for Acne
  • Synthetic Lipids for Skin Healing
  • Importance of Drug Delivery
  • Industry Consolidation

CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS .69

  • Description of Disorders
  • Description of Products
  • Benzoyl Peroxide
  • Description of Products
  • Current Suppliers
  • Retinoids
  • Topical Formulations
  • All-trans Retinoic Acid (Tretinoin)
  • Adapalene
  • Tazarotene
  • Systemic Formulations
  • Isotretinoin
  • Current Suppliers
  • Antibiotics
  • Description of Products
  • Azelaic Acid
  • Clindamycin
  • Erythromycin
  • Metronidazole
  • Sodium Sulfacetamide
  • Others
  • Current Suppliers
  • Oral Contraceptives
  • Research and Development
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • The Future of the Market
  • Competitive Analysis

CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS

  • Overview
  • Description of Products
  • Keratolytics
  • Moisturizers
  • Retinoids
  • Sunscreens
  • Botox and Fillers
  • Research and Development
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • The Future of the Market
  • Competitive Analysis

CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS

  • Overview
  • Description of Products
  • Topical Corticosteroids
  • Systemic Corticosteroids
  • Other Products
  • Research and Development
  • Market Size and Growth
  • Worldwide Market by Type
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Future of the Market
  • Competitive Analysis

CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS

  • Overview
  • Description of Products
  • Systemic Formulations
  • Terbinafine
  • Itraconazole
  • Fluconazole
  • Griseofulvin
  • Ketoconazole
  • Echinocandin
  • Current Suppliers
  • Topical Formulations
  • Polyenes
  • Azoles
  • Miconazole
  • Clotrimazole
  • Ketoconazole
  • Oxiconazole
  • Econazole
  • Sulconazole
  • Allylamines and Benzylamines
  • Naftifine
  • Terbinafine
  • Butenafine
  • Other Topical Formulations
  • Novel Products
  • Current Suppliers
  • Research and Development
  • Market Size and Growth
  • Worldwide Market by Type
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Future of the Market
  • Competitive Analysis

CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS

  • Overview
  • Description of Products
  • Antiandrogens
  • Androgen Inhibitors
  • Other Treatments
  • Research and Development
  • Market Size and Growth
  • Worldwide Market by Type
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Future of the Market
  • Competitive Analysis

CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA AND DEPIGMENTING DRUGS

  • Overview
  • Description of Products
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Research and Development
  • The Future of the Market
  • Competitive Analysis

CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS

  • Overview
  • Description of Products
  • Selected Topical Psoriasis Products
  • Anthralin
  • Coal Tar
  • Methoxsalen
  • Second-generation Retinoids
  • Tazarotene
  • Topical Vitamin D
  • Vitamin D Analogs
  • Vanos
  • Vectical Ointment
  • Selected Systemic Psoriasis Preparations
  • Betamethasone
  • Cortisone Acetate
  • Cyclosporine
  • Hydrocortisone
  • Methotrexate
  • Olopatadine Hydrochloride
  • Tacrolimus
  • Light Therapy
  • Biologics
  • Novel Products
  • Research and Development
  • Market Size and Growth
  • Worldwide Market by Type
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • Future of the Market
  • Competitive Analysis

CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS

  • Overview
  • Nonmelanoma Skin Cancers
  • Actinic Keratoses
  • Basal Cell Carcinoma
  • Squamous Cell Carcinoma
  • Cutaneous T-cell Lymphoma
  • Dysplastic Nevus Syndrome
  • Malignant Melanoma
  • Description of Products
  • 5-Fluorouracil
  • Mechlorethamine/Nitrogen Mustard
  • Carmustine/BCNU (Topical)
  • Vinblastine (Intralesional) and Others
  • Research and Development
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • The Future of the Market
  • Competitive Analysis

CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS

  • Overview
  • Antivirals
  • Antiparasitics
  • Description of Products
  • Antivirals
  • Antiviral Drugs
  • Immunoenhancing Drugs
  • Current Suppliers
  • Antiparasitic Agents
  • Current Suppliers
  • Other Skin Related Products
  • Research and Development
  • Market Size and Growth
  • Worldwide Market
  • Markets by Geographical Region
  • United States
  • Europe
  • Japan
  • Rest of World
  • The Future of the Market
  • Competitive Analysis

CHAPTER THIRTEEN: WORLD MARKET SUMMARY

  • Overview
  • Total Market Size and Forecast
  • Market Analysis by Country
  • United States
  • Europe
  • Japan
  • Rest of World
  • Market and Competitive Analysis

CHAPTER FOURTEEN: CORPORATE PROFILES

  • AbbVie, Inc.
  • Allergan
  • Amgen, Inc.
  • Anacor Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Galderma S.A.
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Company, Inc.
  • Mylan N.V
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • PharmaDerm
  • Stiefel
  • Sinclair IS Pharma Plc.
  • Stratus Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International

APPENDIX

LIST OF COMPANIES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: The Worldwide Market for Prescription Dermatological Drugs 2013, 2015, and 2020
  • Figure 1-1: The Worldwide Market for Prescription Dermatological Drugs 2013, 2015, and 2020

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Common Bases for Topical Dermatological Medications
  • Table 2-2: Worldwide Incidence and Prevalence of Selected Dermatologic Conditions

CHAPTER THREE: ISSUES AND TRENDS

  • Table 3-1: Selected Dermatological Rx-to-OTC Switches
  • Table 3-2: Cy 2015 Relative Value Units (Rvus) and Related Information Used In Determining Final Medicare Payments

CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS

  • Table 4-1: Common Benzoyl Peroxide Formulations
  • Table 4-2: Common Retinoid Formulations
  • Table 4-3: Common Topical Antibiotic Formulations
  • Table 4-3 (continued): Common Topical Antibiotic Formulations
  • Table 4-3 (continued): Common Topical Antibiotic Formulations
  • Table 4-4: Common Oral Contraceptive Formulations
  • Table 4-5: Prescription Acne, Actinic Keratosis and Rosacea Formulations in Development
  • Table 4-6: The Worldwide Market for Prescription Acne and Rosacea Drugs by Type 2013- 2020
  • Figure 4-1: The Worldwide Market for Prescription Acne and Rosacea Drugs Revenues by Type, 2013-2020
  • Figure 4-2: The Worldwide Market for Prescription Acne and Rosacea Drugs Share by Type 2015
  • Figure 4-3: The Worldwide Market for Prescription Acne and Rosacea Drugs Share by Type 2020
  • Table 4-7: Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015 (in millions $)
  • Table 4-8: Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015 (in millions $)
  • Table 4-9: The Worldwide Market for Prescription Antiacne and Rosacea Drugs by Geographical Region 2013-2020
  • Figure 4-4: The Worldwide Market for Prescription Antiacne and Rosacea Drugs Revenues by Geographical Region 2013-2020
  • Figure 4-5: The Worldwide Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2015
  • Figure 4-6: The Worldwide Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2020
  • Table 4-10: Worldwide Market for Prescription Antiacne and Rosacea Drugs Revenues and Market Share by Supplier 2015
  • Figure 4-7: Worldwide Market for Acne and Rosacea Drugs Market Share by Leading Supplier 2015

CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS

  • Table 5-1: Common Prescription Keratolytic Formulations
  • Table 5-2: Occlusive Moisturizers-Categories of Ingredients
  • Table 5-3: Common Prescription Moisturizers
  • Table 5-4: Common Prescription Retinoids for Antiaging and Photodamage
  • Table 5-5: Common Prescription Sunscreens
  • Table 5-6: Other Prescription Antiaging and Photodamage Products
  • Table 5-7: Prescription Antiaging and Photodamage Formulations in Development
  • Table 5-8: The Worldwide Market Antiaging and Photodamage Drugs by Type 2013-2020
  • Figure 5-1: The Worldwide Market for Antiaging and Photodamage Drugs Revenues by Type 2013-2020
  • Figure 5-2: The Worldwide Market for Antiaging and Photodamage Drugs Share by Type 2015
  • Figure 5-3: The Worldwide Market for Antiaging and Photodamage Drugs Share by Type 2020
  • Table 5-9: Top Five EU Countries Prescription Antiaging and Photodamage Drug Markets by Revenues and Percent 2015
  • Table 5-10: Top Four Rest of World Countries Prescription Antiaging and Photodamage Drug Markets by Revenues and Percent 2015
  • Table 5-11: The Worldwide Market for Prescription Antiaging and Photodamage Drugs by Geographical Region 2013-2020
  • Figure 5-4: The Worldwide Market for Prescription Antiaging and Photodamage Drugs, Revenues by Geographical Region 2013-2020
  • Figure 5-5: The Worldwide Market for Antiaging and Photodamage Drugs Share by Geographical Region 2015
  • Figure 5-6: The Worldwide Market for Antiaging and Photodamage Drugs Share by Geographical Region 2020
  • Table 5-12: Worldwide Market for Prescription Antiaging and Photodamage Drugs Revenues and Market Share by Supplier 2015
  • Figure 5-7: Worldwide Market for Prescription Antiaging and Photodamage Drugs, Market Share by Leading Supplier 2015

CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS

  • Table 6-1: Common Prescription Topical Corticosteroid Preparations
  • Table 6-1 (continued): Common Prescription Topical Corticosteroid Preparations
  • Table 6-2: Common Prescription Systemic Corticosteroids
  • Table 6-3: Prescription Other Dermatitis Formulations
  • Table 6-4: Prescription Dermatitis Formulations in Development
  • Table 6-5: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs by Type 2013-2020
  • Figure 6-1: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Type 2013-2020
  • Figure 6-2: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2015
  • Figure 6-3: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2020
  • Table 6-6: Top Five EU Countries Prescription Dermatitis and Seborrhea Drug Markets by Revenues and Percent 2015 (in millions $)
  • Table 6-7: Top Four Rest of World Countries Prescription Dermatitis and Seborrhea Drug Markets by Revenues and Percent 2015 (in millions $)
  • Table 6-8: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs by Geographical Region 2013-2020
  • Figure 6-4: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Geographical Region 2013-2020
  • Figure 6-5: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2015
  • Figure 6-6: The Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2020
  • Table 6-9: Worldwide Market for Prescription Dermatitis and Seborrhea Drugs, Revenues and Market Share by Supplier 2015
  • Figure 6-7: Worldwide Market for Prescription Dermatitis and Seborrhea Drugs Market Share by Leading Supplier 2015

CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS

  • Table 7-1: Common Prescription Systemic Antifungal Dermatological Formulations
  • Table 7-2: Common Prescription Topical Antifungal Dermatological Drugs
  • Table 7-3: Prescription Antifungal Dermatological Drugs in Development
  • Table 7-4: The Worldwide Market for Prescription Antifungal Dermatological Drugs by Type 2013-2020
  • Figure 7-1: The Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues by Type 2013-2020
  • Figure 7-2: The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Type 2015
  • Figure 7-3: The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Type 2020
  • Table 7-5: Top Five EU Countries Prescription Dermatological Antifungal Drug Markets by Revenues and Percent 2015
  • Table 7-6: Top Four Rest of World Countries Prescription Dermatological Antifungal Drug Markets by Revenues and Percent 2015
  • Table 7-7: The Worldwide Market for Prescription Antifungal Dermatological Drugs by Geographical Region 2013-2020
  • Figure 7-4: The Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues by Geographical Region 2013-2020
  • Figure 7-5: The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2015
  • Figure 7-6: The Worldwide Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2020
  • Table 7-8: Worldwide Market for Prescription Antifungal Dermatological Drugs Revenues and Market Share by Supplier 2015
  • Figure 7-7: Worldwide Market for Prescription Antifungal Dermatological Drugs Market Share by Leading Supplier 2015

CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS

  • Table 8-1: Common Prescription Hair Loss or Hair Removal Formulations
  • Table 8-2: Prescription Hair Loss or Hair Removal Formulations in Development
  • Table 8-3: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs by Type 2013-2020
  • Figure 8-1: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Type 2013-2020
  • Figure 8-2: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2015
  • Figure 8-3: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2020
  • Table 8-4: Top Five EU Countries Prescription Dermatological Hair Loss and Hair Removal Drug Markets by Revenues and Percent 2015
  • Table 8-5: Top Four Rest of World Countries Prescription Dermatological Hair Loss and Hair Removal Drug Markets by Revenues and Percent 2015
  • Table 8-6: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Revenues by Geographical Region 2013-2020
  • Figure 8-4: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Revenues by Geographical Region 2013-2020
  • Figure 8-5: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs, Share by Geographical Region 2015
  • Figure 8-6: The Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Share by Geographical Region 2020
  • Table 8-7: Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Revenues and Market Share by Supplier 2015
  • Figure 8-7: Worldwide Market for Prescription Hair Loss and Hair Removal Drugs Market Share by Leading Supplier 2015

CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA AND DEPIGMENTING DRUGS

  • Table 9-1: Common Prescription Hyperpigmentation/Melasma Formulations
  • Table 9-2: Common Prescription Depigmenting Agents
  • Table 9-3: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs by Type 2013-2020
  • Figure 9-1: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs Revenues by Type 2013-2020
  • Figure 9-2: The Worldwide Market for Prescription Hyperpigmentation/ Melasma and Depigmenting Drugs, Share by Type 2015
  • Figure 9-3: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs Share by Type 2020
  • Table 9-4: The Worldwide Market for Prescription Hyperpigmentation/Melasma Drugs by Geographical Region 2013-2020
  • Figure 9-4: The Worldwide Market for Prescription Hyperpigmentation/Melasma Drugs Revenues by Geographical Region 2013-2020
  • Figure 9-5: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs, Share by Geographical Region 2015
  • Figure 9-6: The Worldwide Market for Prescription Hyperpigmentation/Melasma and Depigmenting Drugs, Share by Geographical Region 2020

CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS

  • Table 10-1: Selected Common Prescription Psoriasis Preparations Selected Common Prescription Psoriasis Preparations
  • Table 10-2: Common Prescription Biologics for Psoriasis Treatment
  • Table 10-3: Prescription Psoriasis Preparations in Development
  • Table 10-3 (cont): Prescription Psoriasis Preparations in Development
  • Table 10-4: The Worldwide Market for Prescription Psoriasis Drugs by Type 2013-2020 273
  • Figure 10-1: The Worldwide Market for Prescription Psoriasis Drugs Revenues by Type 2013-2020
  • Figure 10-2: The Worldwide Market for Prescription Psoriasis Drugs Share by Type 2015 275
  • Figure 10-3: The Worldwide Market for Prescription Psoriasis Drugs Share by Type 2020 276
  • Table 10-5: Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015
  • Table 10-6: Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015
  • Table 10-7: The Worldwide Market for Prescription Psoriasis Drugs by Geographical Region 2013-2020
  • Figure 10-4: The Worldwide Market for Prescription Psoriasis Drugs Revenues by Geographical Region 2013-2020
  • Figure 10-5: The Worldwide Market for Prescription Psoriasis Drugs Share by Geographical Region 2015
  • Figure 10-6: The Worldwide Market for Prescription Psoriasis Drugs Share by Geographical Region 2020
  • Table 10-8: Worldwide Market for Prescription Psoriasis Drugs Revenues and Market Share by Supplier 2015
  • Figure 10-7: Worldwide Market for Prescription Psoriasis Drugs Market Share by Leading Supplier 2015

CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS

  • Table 11-1: Malignant Conditions of the Skin
  • Table 11-2: Common Prescription Topical, Intralesional and Other Skin Cancer Agents . 296
  • Table 11-3: Prescription Skin Cancer Preparations in Development
  • Table 11-3 (continued): Prescription Skin Cancer Preparations in Development
  • Table 11-4: The Worldwide Market for Skin Cancer Drugs 2013-2020
  • Figure 11-1: The Worldwide Market for Skin Cancer Drugs 2013-2020
  • Table 11-5: Top Five EU Countries Prescription Psoriasis Markets by Revenues and Percent 2015
  • Table 11-6: Top Four Rest of World Countries Prescription Psoriasis Markets by Revenues and Percent 2015
  • Table 11-7: The Worldwide Market for Prescription Skin Cancer Drugs by Geographical Region 2013-2020
  • Figure 11-2: The Worldwide Market for Prescription Skin Cancer Drugs Revenues by Geographical Region 2013-2020
  • Figure 11-3: The Worldwide Market for Prescription Skin Cancer Drugs Share by Geographical Region 2015
  • Figure 11-4: The Worldwide Market for Prescription Skin Cancer Drugs Share by Geographical Region 2020
  • Table 11-8: Worldwide Market for Prescription Skin Cancer Drugs Revenues and Market Share by Supplier 2015
  • Figure 11-5: Worldwide Market for Skin Cancer Drugs Market Share by Leading Supplier 2015

CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS

  • Table 12-1: Common Prescription Dermatological Systemic and Topical Antiviral Formulations
  • Table 12-2: Common Prescription Topical Antiparasitic Formulations
  • Table 12-3: Common Prescription Other Skin Formulations
  • Table 12-4: Prescription Miscellaneous Skin Preparations in Development
  • Table 12-5: The Worldwide Market for Prescription Miscellaneous Skin Disorder Drugs by Type 2013-2020
  • Figure 12-1: The Worldwide Market for Miscellaneous Skin Disorder Drugs Revenues by Type 2013-2020
  • Figure 12-2: The Worldwide Market for Miscellaneous Skin Disorder Drugs Share by Type 2015
  • Figure 12-3: The Worldwide Market for Miscellaneous Skin Disorder Drugs Share by Type 2020
  • Table 12-6: Top Five EU Countries Prescription Miscellaneous Skin Disorder Drug Markets by Revenues and Percent 2015
  • Table 12-7: Top Four Rest of World Countries Prescription Miscellaneous Skin Disorder Drug Markets by Revenues and Percent 2015
  • Table 12-8: The Worldwide Market for Prescription Miscellaneous Skin Disorder Drugs by Geographical Region 2013-2020
  • Figure 12-4: The Worldwide Market for Prescription Miscellaneous Drugs Revenues by Geographical Region 2013-2020
  • Figure 12-5: The Worldwide Market for Prescription Miscellaneous Drugs Share by Geographical Region 2015
  • Figure 12-6: The Worldwide Market for Prescription Miscellaneous Drugs Share by Geographical Region 2020

CHAPTER THIRTEEN: WORLD MARKET SUMMARY

  • Table 13-1: The Worldwide Market for Prescription Dermatological Drugs, Revenues by Segment, 2013-2020
  • Figure 13-1: The Worldwide Market for Prescription Dermatological Drugs Revenues by Dermatological Segment 2013-2020
  • Figure 13-2: The Worldwide Market for Dermatological Drugs Market Share by Type 2015
  • Figure 13-3: The Worldwide Market for Dermatological Drugs Market Share by Type 2020
  • Table 13-2: Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2015
  • Figure 13-4: Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2015
  • Figure 13-5: Worldwide Prescription Dermatological Drug Market Analysis by Region/Country, 2020
  • Table 13-3: Worldwide Market for Prescription Dermatological Drugs Segments of Major Participation by Manufacturer 2015
  • Table 13-4: Worldwide Market for Prescription Dermatological Drug Revenues and Market Share by Supplier 2015

LIST OF COMPANIES

Back to Top